LeMaitre (LMAT) Q2 2026 earnings review
Flawless Execution Drives Massive Operating Leverage
LeMaitre Vascular delivered a textbook quarter of profitable growth. While revenue growth held stable at 10% YoY, operating income surged 26%. The secret? Extreme headcount restraint and aggressive pricing power. The company managed to expand gross margins by 210 basis points while holding total headcount completely flat versus a year ago (660 vs 658). The Artegraft international rollout remains the star engine, offsetting expected weakness in the catheter segment. While the Americas segment is decelerating, the overarching story is one of expanding profitability and a rapidly growing cash hoard.
🐂 Bull Case
Gross margins expanded 210 bps to 72.1% and operating margins hit 29%. LeMaitre is proving it can extract massive bottom-line value from its niche product portfolio through price hikes and operational efficiencies.
Artegraft sales surged 34% in Q2. Approvals in 56 countries mean the company's largest product is also its fastest-growing product, validating the international go-direct strategy.
🐻 Bear Case
The Americas segment—LeMaitre's largest—grew just 5% YoY in Q2, significantly lagging the company average and decelerating from 12% a year ago.
The balance sheet holds $376.2M in cash (over 5x annual operating income). Without meaningful M&A deployment, this massive balance acts as a drag on return on equity.
⚖️ Verdict: 🟢
Bullish. The 10% top-line growth is highly resilient, and management's ability to drive 20%+ earnings growth via strict cost control is exceptional. A slight deceleration in the Americas is the only real blemish on a pristine print.
Key Themes
Artegraft OUS Launch Accelerating
Artegraft continues to carry the top line, with worldwide sales accelerating 34% YoY. The product is now approved in 56 countries and accounts for 21% of total sales. Management is heavily investing in the infrastructure to support this, currently undertaking six international warehouse expansions to facilitate direct sales.
Relentless Operating Leverage
LeMaitre's operating leverage is structural, not a fluke. Operating income grew 26% on just 10% sales growth. The primary driver: extreme headcount restraint. The company ended Q2 with 660 employees, virtually unchanged from 658 a year ago. By increasing prices and holding fixed costs flat, incremental revenue is dropping almost entirely to the bottom line.
EMEA and APAC Driving Volume
International markets are the primary volume growth engines, with both EMEA and APAC reporting stable, high 18% YoY growth in Q2. This outperformance is a direct result of the company's continuous transition to direct sales models abroad.
Americas Segment Decelerating
Despite the rosy overall picture, there is a clear red flag in the geographic mix. The Americas segment grew just 5% in Q2. This represents a steady deceleration from 10% in late 2025 and 12% a year ago. It contradicts the 'record sales' narrative and suggests core U.S. market volume might be plateauing under the weight of aggressive price hikes.
Catheter Base Effect Causes Reversal
Catheter sales reversed, dropping 11% in the quarter. Management clearly telegraphed this, citing a recall-driven overstocking event in Q2 2025 that created a brutally tough comparable. Excluding catheters, underlying organic growth was actually 12%, but this segment will require monitoring to ensure it returns to normalized growth in Q3.
Macro FX Masking Underlying Strength
Foreign exchange rate fluctuations remain a persistent macro headwind. On a constant currency and adjusted basis, Q2 organic growth was strong at 10%. Without currency drags, the international outperformance would look even more pronounced on the reported GAAP statements.
Other KPIs
Accelerating. Up 210 basis points YoY. Management attributed the gain to higher prices, a favorable mix shift (higher-margin Artegraft outperforming lower-margin distributed products), and manufacturing efficiencies. The margin profile proves high pricing power in niche vascular categories.
Stable and compounding. Cash increased $9.0 million sequentially. The company has immense strategic optionality, yet management remains highly disciplined (or overly cautious) regarding M&A. They are deploying some capital via a $0.25 quarterly dividend and a $100M active share repurchase program.
Guidance
Stable. The midpoint implies 10% reported and 11% organic YoY growth. This represents a continuation of the steady double-digit trajectory seen over the last year, indicating the catheter comp headwind from Q2 will dissipate.
Decelerating sequentially. The guidance implies 7% YoY adjusted growth, a step down from the 26% GAAP growth seen in Q2. Management expects a 27% operating margin, likely reflecting investments in the six new international warehouses mentioned in the release.
Stable. Implies 11% full-year organic growth. The company has historically been conservative with initial annual guidance and tends to meet or beat these steady targets.
Accelerating. The midpoint projects 21% adjusted EPS growth for the full year. This confirms that the severe operating leverage seen in H1 is expected to persist through the entirety of 2026.
Key Questions
Americas Deceleration
Americas sales growth slowed to 5% this quarter. How much of this is volume elasticity pushing back against consecutive years of 8% price hikes versus market share losses?
M&A vs Cash Hoard
Cash has now reached $376 million. If organic growth continues to outpace the M&A hurdle rate, will the board consider accelerating the $100M buyback or issuing a special dividend?
Catheter Normalization
With the Q2 2025 recall stocking anomaly now behind you, what is the underlying normalized growth rate for the catheter business heading into Q3 and Q4?